OVID (Ovid Therapeutics) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 02, 2026)


OVID Ovid Therapeutics Inc OVID
48 GF Score
Price $2.77
GF Value $8.41
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ovid Therapeutics 5-Year Yield-on-Cost %?

Ovid Therapeutics OVID +3.75% 48 5-Year Yield-on-Cost % is 0.00 as of Jul. 02, 2026. GuruFocus rates OVID with a GF Score™ of 48/100 and a GF Value™ of $8.41 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 153 Biotechnology companies, Ovid Therapeutics ranks worse than 653594.12% on this metric.

Ovid Therapeutics's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Ovid Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



OVID's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.75
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Ovid Therapeutics  (NAS:OVID) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Ovid Therapeutics 5-Year Yield-on-Cost % Related Terms


OVID vs ARTV, CCCC, RZLT: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Ovid Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's 5-Year Yield-on-Cost % falls into.


OVID
48GF Score
Ovid Therapeutics Inc OVID
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Ovid Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Ovid Therapeutics (OVID) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 02, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ovid Therapeutics and its competitors. According to the industry distribution chart, Ovid Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry.
Is Ovid Therapeutics' 5-Year Yield-on-Cost % too high?
Ovid Therapeutics' current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Ovid Therapeutics ranks #999999 out of 153 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' 5-Year Yield-on-Cost % compare to ARTV and CCCC?
According to the Biotechnology industry distribution chart, Ovid Therapeutics ranks #999999 out of 153 companies for 5-Year Yield-on-Cost %. This places Ovid Therapeutics in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.75, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Ovid Therapeutics and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ovid Therapeutics's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.41, compared to a current price of $2.77 — trading 67.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.77 is trading 67.1% below its estimated GF Value™ of $8.41. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: $8.41 vs. price of $2.77 (67.1% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score

Get the complete analysis for OVID

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.77
Price
$8.41
GF Value